Autopsy report · NCT04093362

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

“Due to Poor Recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 3 years 4 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Taiho Oncology, Inc.

Sponsor type

Industry

Conditions

Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements

Interventions

Futibatinib; Cisplatin; Gemcitabine

Participants

10

Sites

103

Countries

Argentina, Australia, Belgium, Brazil, France, Germany, Hong Kong, Italy, Japan, Mexico, Netherlands, Peru and more

Trials that died the same way

• Antidepressant Effects of TS-161 in Treatment-Resistant Depression
  “due to low recruitment” (95% match in meaning)
• Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas
  “due to lack of recruitment” (94% match in meaning)
• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (89% match in meaning)
• BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions
  “Due to low recruitment rate” (89% match in meaning)
• Effect of Nasaleze on Nasal Challenge With Allergen
  “Poor recruitment” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.